N-(4-chlorophenyl)-N'-isopropyl-6-methyl-[1,3,5]-triazine-2,4-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: N-(4-chlorophenyl)-N'-isopropyl-6-methyl-[1,3,5]-triazine-2,4-diamine
• 英文别名: N²-(4-chloro-phenyl)-N⁴-isopropyl-6-methyl-[1,3,5]triazine-2,4-diyldiamine；N²-(4-Chlor-phenyl)-N⁴-isopropyl-6-methyl-[1,3,5]triazin-2,4-diyldiamin；4-N-(4-chlorophenyl)-6-methyl-2-N-propan-2-yl-1,3,5-triazine-2,4-diamine
• 化学式: C₁₃H₁₆ClN₅
• 分子量: 277.757
• InChiKey: XLNXNRITLWFSEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  62.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  氯胍 、 乙酰氯 在 吡啶 作用下， 以52.2%的产率得到N-(4-chlorophenyl)-N'-isopropyl-6-methyl-[1,3,5]-triazine-2,4-diamine
  参考文献：
  名称：

  一种简便的一锅合成2，4-二氨基-6-取代的S-三嗪衍生物

  摘要：

  报道了一种新颖且容易的一锅法制备2，4-二氨基-6-取代的-s-三嗪衍生物（IIa-n）。通过大量示例演示了其应用范围。新方法包括在冰冷温度下，用吡啶中的酰氯或烷基氯氧乙酸乙酸酯处理丙胍或氯丙胍，然后回流过夜，得到所需产物的良好收率。

  DOI：

  10.1002/jhet.5570450618

文献信息

• Biguanide compositions and methods of treating metabolic disorders
  申请人：Elcelyx Therapeutics, Inc.

  公开号：US10028923B2

  公开（公告）日：2018-07-24

  Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

  本文提供了通过施用包含双胍类或相关杂环化合物（如二甲双胍）的组合物来治疗某些疾病（包括糖尿病、肥胖症和其他代谢性疾病、失调或病症）的方法。本文还提供了双胍类或相关杂环化合物组合物及其用于本发明方法的制备方法。本文还提供了包含二甲双胍及其盐类的组合物和使用方法。
• Compositions and methods for treating metabolic disorders
  申请人：Anji Pharma (US) LLC

  公开号：US10603291B2

  公开（公告）日：2020-03-31

  Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.

  本发明提供了改善双胍类化合物的胃肠道耐受性以及治疗代谢紊乱和/或使有需要的患者，特别是双胍类化合物治疗禁忌症患者减轻体重的方法，包括针对小肠施用包括二甲双胍在内的此类双胍类化合物的缓释制剂。
• BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS
  申请人：Anji Pharma (US) LLC

  公开号：EP2800561B1

  公开（公告）日：2020-08-19
• Biguanide Compositions and Methods of Treating Metabolic Disorders
  申请人：Baron Alain D.

  公开号：US20130095140A1

  公开（公告）日：2013-04-18

  Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
• Compositions and Methods of Treating Metabolic Disorders
  申请人：Elcelyx Therapeutics, Inc.

  公开号：US20130177604A1

  公开（公告）日：2013-07-11

  Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.